

Chiara Chiozzini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4384296/publications.pdf>

Version: 2024-02-01

49
papers

1,645
citations

279701

23
h-index

302012

39
g-index

53
all docs

53
docs citations

53
times ranked

1979
citing authors

#	ARTICLE	IF	CITATIONS
1	Strong SARS-CoV-2 N-Specific CD8+ T Immunity Induced by Engineered Extracellular Vesicles Associates with Protection from Lethal Infection in Mice. <i>Viruses</i> , 2022, 14, 329.	1.5	11
2	Extracellular Vesicles and Their Use as Vehicles of Immunogens. <i>Methods in Molecular Biology</i> , 2022, 2504, 177-198.	0.4	0
3	Activation of Anti-SARS-CoV-2 Human CTLs by Extracellular Vesicles Engineered with the N Viral Protein. <i>Vaccines</i> , 2022, 10, 1060.	2.1	4
4	Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 37.	3.5	8
5	Simultaneous CD8+ T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs. <i>Vaccines</i> , 2021, 9, 240.	2.1	20
6	The C-Terminal Domain of Nefmut Is Dispensable for the CD8+ T Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles. <i>Vaccines</i> , 2021, 9, 373.	2.1	4
7	Long-Term Antitumor CD8+ T Cell Immunity Induced by Endogenously Engineered Extracellular Vesicles. <i>Cancers</i> , 2021, 13, 2263.	1.7	5
8	Targeting Human Papillomavirus-Associated Cancer by Oncoprotein-Specific Recombinant Antibodies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9143.	1.8	5
9	Extracellular vesicle-mediated intercellular communication in HIV-1 infection and its role in the reservoir maintenance. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 40-48.	3.2	6
10	KSHV G-protein coupled receptor vGPCR oncogenic signaling upregulation of Cyclooxygenase-2 expression mediates angiogenesis and tumorigenesis in Kaposi's sarcoma. <i>PLoS Pathogens</i> , 2020, 16, e1009006.	2.1	7
11	N-Terminal Fatty Acids of NEFMUT Are Required for the CD8+ T-Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles. <i>Vaccines</i> , 2020, 8, 243.	2.1	8
12	Engineered Extracellular Vesicles/Exosomes as a New Tool against Neurodegenerative Diseases. <i>Pharmaceutics</i> , 2020, 12, 529.	2.0	11
13	Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes. <i>Cancers</i> , 2019, 11, 138.	1.7	30
14	Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs. <i>Journal of Molecular Medicine</i> , 2019, 97, 1139-1153.	1.7	4
15	Role of Extracellular Vesicles in Human Papillomavirus-Induced Tumorigenesis. , 2019, , .		0
16	<p>The Intracellular Delivery Of Anti-HPV16 E7 scFvs Through Engineered Extracellular Vesicles Inhibits The Proliferation Of HPV-Infected Cells</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 8755-8768.	3.3	18
17	An Exosome-Based Vaccine Platform Imparts Cytotoxic T Lymphocyte Immunity Against Viral Antigens. <i>Biotechnology Journal</i> , 2018, 13, e1700443.	1.8	77
18	Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells. <i>Journal of Molecular Medicine</i> , 2018, 96, 211-221.	1.7	29

#	ARTICLE	IF	CITATIONS
19	DNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and Tumors. <i>Molecular Biotechnology</i> , 2018, 60, 773-782.	1.3	24
20	Exosomes in Therapy: Engineering, Pharmacokinetics and Future Applications. <i>Current Drug Targets</i> , 2018, 20, 87-95.	1.0	34
21	Trans-dissemination of exosomes from HIV-1-infected cells fosters both HIV-1 trans-infection in resting CD4+ T lymphocytes and reactivation of the HIV-1 reservoir. <i>Archives of Virology</i> , 2017, 162, 2565-2577.	0.9	11
22	Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 4579-4591.	3.3	58
23	The CD8+ T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIX™ Adjuvant. <i>Vaccines</i> , 2016, 4, 42.	2.1	13
24	Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1. <i>Retrovirology</i> , 2015, 12, 87.	0.9	77
25	HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET. <i>Current Drug Targets</i> , 2015, 17, 33-45.	1.0	19
26	HPV-E7 Delivered by Engineered Exosomes Elicits a Protective CD8+ T Cell-Mediated Immune Response. <i>Viruses</i> , 2015, 7, 1079-1099.	1.5	47
27	Uncovering the role of defective HIV-1 in spreading viral infection. <i>Future Virology</i> , 2015, 10, 371-381.	0.9	1
28	Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner. <i>Aids</i> , 2014, 28, 2189-2200.	1.0	24
29	Cell activation and HIV-1 replication in unstimulated CD4+T lymphocytes ingesting exosomes from cells expressing defective HIV-1. <i>Retrovirology</i> , 2014, 11, 46.	0.9	52
30	<i>In vivo</i> antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16. <i>International Journal of Cancer</i> , 2014, 134, 2742-2747.	2.3	27
31	Exosomes from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Cells License Quiescent CD4 ⁺ T Lymphocytes To Replicate HIV-1 through a Nef- and ADAM17-Dependent Mechanism. <i>Journal of Virology</i> , 2014, 88, 11529-11539.	1.5	140
32	The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells. <i>Angiogenesis</i> , 2014, 17, 831-838.	3.7	13
33	HIV-1 Nef Impairs Key Functional Activities in Human Macrophages through CD36 Downregulation. <i>PLoS ONE</i> , 2014, 9, e93699.	1.1	16
34	A Role for Virally Induced Reactive Oxygen Species in Kaposi's Sarcoma Herpesvirus Tumorigenesis. <i>Antioxidants and Redox Signaling</i> , 2013, 18, 80-90.	2.5	54
35	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. <i>PLoS ONE</i> , 2012, 7, e48781.	1.1	56
36	Human immunodeficiency virus protease inhibitors reduce the growth of human tumors <i>in vivo</i> a proteasome-independent block of angiogenesis and matrix metalloproteinases. <i>International Journal of Cancer</i> , 2011, 128, 82-93.	2.3	40

#	ARTICLE	IF	CITATIONS
37	Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. <i>Virology</i> , 2009, 395, 45-55.	1.1	39
38	Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which requires binding of Tat to viral particles. <i>Journal of Gene Medicine</i> , 2009, 11, 955-965.	1.4	26
39	Primary Effusion Lymphoma Cells Undergoing Human Herpesvirus Type 8 Productive Infection Produce C-Type Retroviral Particles. <i>International Journal of Immunopathology and Pharmacology</i> , 2008, 21, 999-1006.	1.0	4
40	In Vivo-Restricted and Reversible Malignancy Induced by Human Herpesvirus-8 KSHV: A Cell and Animal Model of Virally Induced Kaposi's Sarcoma. <i>Cancer Cell</i> , 2007, 11, 245-258.	7.7	148
41	In Vivo-Restricted and Reversible Malignancy Induced by Human Herpesvirus-8 KSHV: A Cell and Animal Model of Virally Induced Kaposi's Sarcoma. <i>Cancer Cell</i> , 2007, 11, 471.	7.7	0
42	Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. <i>Infectious Agents and Cancer</i> , 2006, 1, 6.	1.2	30
43	HIV-1 Tat Regulates Endothelial Cell Cycle Progression via Activation of the Ras/ERK MAPK Signaling Pathway. <i>Molecular Biology of the Cell</i> , 2006, 17, 1985-1994.	0.9	66
44	Intracellular anti-E7 human antibodies in single-chain format inhibit proliferation of HPV16-positive cervical carcinoma cells. <i>International Journal of Cancer</i> , 2005, 116, 564-570.	2.3	26
45	Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. <i>Cancer Cell</i> , 2003, 3, 131-143.	7.7	221
46	Human antibody response to Toscana virus glycoproteins expressed by recombinant baculovirus. <i>Journal of Medical Virology</i> , 2002, 68, 615-619.	2.5	13
47	Clearance of Human Herpesvirus 8 from Blood and Regression of Leukopenia-Associated Aggressive Classic Kaposi's Sarcoma during Interferon- α Therapy: A Case Report. <i>Clinical Infectious Diseases</i> , 2001, 33, 1782-1785.	2.9	7
48	Activity of Toscana and Rift Valley fever virus transcription complexes on heterologous templates. <i>Journal of General Virology</i> , 2001, 82, 781-785.	1.3	33
49	Alpha Interferon Inhibits Human Herpesvirus 8 (HHV-8) Reactivation in Primary Effusion Lymphoma Cells and Reduces HHV-8 Load in Cultured Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 1999, 73, 4029-4041.	1.5	70